OXFD - オックスフォ―ド・イミュノテック・グロ―バル (Oxford Immunotec Global PLC) オックスフォ―ド・イミュノテック・グロ―バル

 OXFDのチャート


 OXFDの企業情報

symbol OXFD
会社名 Oxford Immunotec Global Plc (オックスフォ―ド・イミュノテック・グロ―バル)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 オックスフォード・イムノテック・グローバル(Oxford Immunotec Global PLC)は診断会社である。同社は主に、不十分な免疫調節状態の試験を開発、商品化する。同社の製品ライン及び開発活動は、主に感染症、移植、自己免疫と炎症性疾患および免疫腫瘍学の4つの分野に焦点を当てる。T-SPOT.TB検査は、免疫調節された状態の患者の診断、予後およびモニタリングを知らせるために特定の免疫細胞の応答を測定することを可能にする結核(TB)検査、感染検査、T-SPOT技術プラットフォームである。同社はイムゲンと免疫学の買収により得られたライム病などのダニ媒介疾患のアッセイを提供する。同社にはダニ媒介性疾患の専門知識を基に、血液スクリーニングに使用するための一連のアッセイがある。T-SPOT. CMVとT-SPOT. PRT検査は、移植市場に特化した製品ラインの一部である。   オックスフォ―ド・イミュノテック・グロ―バルは英国の医療診断会社。独自の結核菌感染検査「T-スポット」技術に基づき、疾病の試験薬・キットを開発する。ELISA法を使用した結核補助診断キット同社の「T-スポット.TB」検査は、米国、一部欧州、および日本で直接販売され、その他市場では販売業者を通じて販売されている。   Oxford Immunotec Global Plc operates as a diagnostics company, which develops and commercializes proprietary tests for immunology and infectious disease. Its products include T-SPOT.TB, T-SPOT.CMV, T-SPOT.PRT and T-CELL XTEND. The company was founded by Peter James Wrighton-Smith in 2002 and is headquartered in Abingdon, the United Kingdom.
本社所在地 94C Innovation Drive Milton Park Abingdon OX14 4RZ GBR
代表者氏名 Richard A. Sandberg リチャード・A・サンドバーグ
代表者役職名 Independent Chairman of the Board
電話番号 +44 1235-44-2780
設立年月日 2013年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 457人
url www.oxfordimmunotec.com
nasdaq_url https://www.nasdaq.com/symbol/oxfd
adr_tso
EBITDA EBITDA(百万ドル) -18.19400
終値(lastsale) 16.19
時価総額(marketcap) 420415719.23
時価総額 時価総額(百万ドル) 413.92380
売上高 売上高(百万ドル) 106.14300
企業価値(EV) 企業価値(EV)(百万ドル) 377.89080
当期純利益 当期純利益(百万ドル) -3.44400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Oxford Immunotec Global PLC revenues increased 6% to $50.7M. Net loss decreased 32% to $16.8M. Revenues reflect United States segment increase of 5% to $31.1M Asia segment increase of 6% to $15.1M. Lower net loss reflects Settlement expense decrease of 82% to $1.8M (expense) General and administrative decrease of 6% to $12.6M (expense).

 OXFDのテクニカル分析


 OXFDのニュース

   The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid  2020/06/05 11:34:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.
   KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources  2020/06/04 22:14:00 MarketScreener
By Greg Roumeliotis A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics…
   Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates  2020/05/05 13:15:15 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Richard A. Sandberg Sells 3,000 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock  2019/11/07 15:12:54 Modern Readers
Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. NASDAQ:OXFD opened at $16.72 on Thursday. The company has a quick ratio of 12.76, a current […]
   The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid  2020/06/05 11:34:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In Focus Adamas' Regulatory Application For Label Expansion For Parkinson's Drug Accepted For Review Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) said the FDA has accepted its sNDA for Gocovri as a treatment for OFF episodes in Parkinson's disease patients receiving levodopa-based therapy.
   KKR, Ambersand Capital in joint bid for Oxford Immunotec: sources  2020/06/04 22:14:00 MarketScreener
By Greg Roumeliotis A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics…
   Oxford Immunotec (OXFD) Reports Q1 Loss, Lags Revenue Estimates  2020/05/05 13:15:15 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of -185.71% and -1.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Richard A. Sandberg Sells 3,000 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock  2019/11/07 15:12:54 Modern Readers
Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. NASDAQ:OXFD opened at $16.72 on Thursday. The company has a quick ratio of 12.76, a current […]
   Richard A. Sandberg Sells 3,000 Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) Stock  2019/11/07 15:12:54 Modern Readers
Oxford Immunotec Global PLC (NASDAQ:OXFD) Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. NASDAQ:OXFD opened at $16.72 on Thursday. The company has a quick ratio of 12.76, a current […]
   Exclusive: Oxford Immunotec explores sale following takeover interest - sources  2019/09/23 19:08:53 Reuters
Oxford Immunotec Global Plc , a medical diagnostics company that develops tests to identify tuberculosis, is exploring strategic alternatives, including a potential sale, people familiar with the matter said on Monday.
   Oxford Immunotec (OXFD) Beats Q2 Earnings and Revenue Estimates  2019/08/06 13:45:07 Zacks Investment Research
Oxford Immunotec (OXFD) delivered earnings and revenue surprises of 140.00% and 0.76%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   Retail On Display (Stocks To Watch Podcast)  2019/05/19 11:35:57 Seeking Alpha
   Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2019 Results - Earnings Call Transcript  2019/05/13 23:35:08 Seeking Alpha
Oxford Immunotec Global PLC (NASDAQ:OXFD) Q1 2019 Results Conference Call May 09, 2019 08:00 AM ET Company Participants Peter Wrighton-Smith - CEO Matt McLaughl

 関連キーワード  (先端医療機器_テクノロジ― 米国株 オックスフォ―ド・イミュノテック・グロ―バル OXFD Oxford Immunotec Global PLC)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)